CHARLOTTESVILLE, Va., July 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer and ...
* Says diffusion plans to initiate this clinical trial by end of 2017 * Diffusion Pharmaceuticals- interacting with FDA regarding design, execution of planned phase 3 study, with initiation planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results